Home » FDA APPROVES ORAL FORMULATION OF ABILIFY
FDA APPROVES ORAL FORMULATION OF ABILIFY
Bristol-Myers Squibb and Otsuka Pharmaceutical have received approval from the FDA for an oral solution formulation of Abilify, a treatment for schizophrenia and acute manic and mixed episodes associated with bipolar disorder.
The companies said the oral formulation of Abilify (aripiprazole) will be available in pharmacies beginning in February.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct